外显子组测序对胎儿结构异常产前诊断诊断率的系统评价与Meta分析
该系统评价与Meta分析纳入66项研究、4350例胎儿,评估染色体核型/染色体微阵列(CMA)正常时产前外显子组测序(ES)的增量诊断率。ES的合并增量诊断率为31%(95%CI 26%-36%,p<0.0001),预先筛选可能为单基因病因的病例诊断率显著高于未筛选病例(42% vs 15%,p<0.0001),不同表型亚组诊断率从孤立性骨骼异常的53%到孤立性颈项透明层增厚的2%不等。
要点
- CMA/核型正常时,产前ES对结构异常胎儿的合并增量诊断率为31%(95%CI 26%-36%)。
- 预先筛选可能为单基因病因的病例诊断率42%,显著高于未筛选病例的15%。
- 孤立性骨骼异常诊断率53%,孤立性颈项透明层增厚诊断率2%。
核心结论
- 当CMA/核型未提供诊断时,产前ES可为额外31%的结构异常胎儿提供诊断。
- 预期诊断率取决于受累的器官系统,并可通过多学科审查预先筛选可能为单基因病因的病例来优化。
研究设计与样本
- 系统评价与Meta分析,检索四个电子数据库,纳入≥10例结构异常胎儿接受ES或全基因组测序的研究。
- 共纳入66项研究的72篇报告,代表4350例胎儿。
主要发现
- ES的合并增量诊断率为31%(95%CI 26%-36%,p<0.0001)。
- 预先筛选可能为单基因病因的病例诊断率显著高于未筛选病例(42% vs 15%,p<0.0001)。
- 表型亚组间诊断率差异显著,从孤立性骨骼异常的53%(95%CI 42%-63%,p<0.0001)到孤立性颈项透明层增厚的2%(95%CI 0%-5%,p=0.04)。
关键数值与推荐
- ES的合并增量诊断率为31%(95%CI 26%-36%,p<0.0001)。
- 预先筛选可能为单基因病因的病例诊断率为42%,未筛选病例为15%(p<0.0001)。
- 孤立性骨骼异常诊断率为53%(95%CI 42%-63%,p<0.0001)。
- 孤立性颈项透明层增厚诊断率为2%(95%CI 0%-5%,p=0.04)。
临床怎么用
- 产前ES可在CMA/核型正常时对结构异常胎儿提供额外诊断,预期诊断率取决于受累器官系统。
- 作者认为可通过多学科审查预先筛选可能为单基因病因的病例来优化诊断率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We conducted a systematic review and meta-analysis to determine the diagnostic yield of exome sequencing (ES) for prenatal diagnosis of fetal structural anomalies, where karyotype/chromosomal microarray (CMA) is normal. METHODS: Following electronic searches of four databases, we included studies with ≥10 structurally abnormal fetuses undergoing ES or whole genome sequencing. The incremental diagnostic yield of ES over CMA/karyotype was calculated and pooled in a meta-analysis. Sub-group analyses investigated effects of case selection and fetal phenotype on diagnostic yield. RESULTS: We identified 72 reports from 66 studies, representing 4350 fetuses. The pooled incremental yield of ES was 31% (95% confidence interval (CI) 26%-36%, p < 0.0001). Diagnostic yield was significantly higher for cases pre-selected for likelihood of monogenic aetiology compared to unselected cases (42% vs. 15%, p < 0.0001). Diagnostic yield differed significantly between phenotypic sub-groups, ranging from 53% (95% CI 42%-63%, p < 0.0001) for isolated skeletal abnormalities, to 2% (95% CI 0%-5%, p = 0.04) for isolated increased nuchal translucency. CONCLUSION: Prenatal ES provides a diagnosis in an additional 31% of structurally abnormal fetuses when CMA/karyotype is non-diagnostic. The expected diagnostic yield depends on the body system(s) affected and can be optimised by pre-selection of cases following multi-disciplinary review to determine that a monogenic cause is likely.
引用
- Mellis R, Oprych K, Scotchman E, et al. Diagnostic yield of exome sequencing for prenatal diagnosis of fetal structural anomalies: A systematic review and meta-analysis. Prenat Diagn. 2022. PMID: 35170059. doi:10.1002/pd.6115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。